Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
The University of Texas Southwestern Medical Center · Kyoto University · +1 more institution
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
7
total citations
- FWCI
- 95.56
- Percentile
- 100%
- References
- 24
Too recent for citation history.
Authors
137Topics & keywords
Topics
Keywords
- Semaglutide
- Type 2 diabetes
- Clinical trial
- Diabetes mellitus
- Phases of clinical research
No related works found for this paper.